http://en.people.cn/n3/2025/0409/c90000-20299523.html

Healthgen Biotechnology in Wuhan, a biopharmaceutical company, has realized large-scale production of rice-derived albumin. https://www.oryzogen.net/list/19.html

According to the company, annual production capacity can reach 10 tonnes of HSA stock solution. Once a new factory starts operations in 2026, the combined annual production capacity of both factories will reach 130 tonnes, which is expected to replace about 25 percent of the HSA imported from abroad. China produced and imported more than 1,000 t of HSA in 2024, with imports accounting for over 69 percent.

The company has partnered with over 40 top-tier hospitals nationwide on clinical trials. The results of Phase III clinical trials showed that “the efficacy of the company’s rice-derived human serum albumin is equivalent to that of plasma-derived protein,” according to the company. The HSA product developed using this technology has completed Phase III of its clinical trials, and is expected to pass National Medical Products Administration registration in June 2025.